Percutaneous Transluminal Coronary Angioplasty: Multimedia

References

1. Cavusoglu E, Kini AS, Marmur JD, Sharma SK. Current status of rotational atherectomy. Catheter Cardiovasc Interv. Aug 2004;62(4):485-98. [Medline].

2. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. Jul 1 1997;96(1):91-8. [Medline].

3. Vandormael M, Preusler W. Six months follow-up results following excimer laser angioplasty, rotational atherectomy and balloon angioplasty for complex lesions: ERBAC Study. Circulation. 1994:90.

4. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. Mar 19 2002;105(11):1285-90. [Medline].

5. Zimarino M, Corcos T, Favereau X, et al. Rotational coronary atherectomy with adjunctive balloon angioplasty for the treatment of ostial lesions. Cathet Cardiovasc Diagn. Sep 1994;33(1):22-7. [Medline].

6. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. Feb 10 2009;53(6):530-53. [Medline].

7. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. Jun 5 2007;115(22):2842-7. [Medline].

8. Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. Sep 10-16 2005;366(9489):914-20. [Medline].

9. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. Sep 7 2002;360(9335):743-51. [Medline].

10. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. Jan 2 1992;326(1):10-6. [Medline].

11. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. Aug 16 1997;350(9076):461-8. [Medline].

12. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. Jul 8 1999;341(2):70-6. [Medline].

13. Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am Coll Cardiol. Sep 29 2009;54(14):1303-8. [Medline].

14. Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. May 19 2004;43(10):1743-51. [Medline].

15. Hueb WA, Soares PR, Almeida De Oliveira S. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. Nov 9 1999;100(19 Suppl):II107-13.

16. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. May 7 2009;360(19):1946-59. [Medline].

17. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. Oct 1 2003;42(7):1161-70. [Medline].

18. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet. Oct 31 1998;352(9138):1419-25. [Medline].

19. Alderman EL, Kip KE, Whitlow PL, Bashore T, Fortin D, Bourassa MG. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. Aug 18 2004;44(4):766-74. [Medline].

20. Pocock SJ, Henderson RA, Rickards AF, ey al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet. Nov 4 1995;346(8984):1184-9. [Medline].

21. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol. Oct 1993;22(4):1060-7. [Medline].

22. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. Nov 23 2006;355(21):2203-16. [Medline].

23. [Best Evidence] Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. Apr 4 2009;373(9670):1190-7. [Medline].

24. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. Aug 25 1994;331(8):489-95. [Medline].

25. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. Aug 25 1994;331(8):496-501. [Medline].

26. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. Aug 16 2005;46(4):575-81. [Medline].

27. Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. Aug 16 2005;46(4):582-8. [Medline].

28. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. May 26 2005;352(21):2174-83. [Medline].

29. Serruys PW, Lemos PA, van Hout BA,. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart. Sep 2004;90(9):995-8. [Medline].

30. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. Jun 18 1998;338(25):1785-92. [Medline].

31. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. Dec 1995;26(7):1643-50. [Medline].

32. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].

33. Poole-Wilson PA, Pocock SJ, Fox KA, Henderson RA, Wheatley DJ, Chamberlain DA. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial. Heart. Oct 2006;92(10):1473-9. [Medline].

34. Luciardi H, Muntaner J, Berman S, de la Serna F, Costantini C. [Acute coronary syndromes without ST segment elevation. Why should we take an interventionist approach?]. Arch Cardiol Mex. Oct-Dec 2001;71(4):295-305. [Medline].

35. Hirsch A, Windhausen F, Tijssen JG, et al. Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. Eur Heart J. Mar 2009;30(6):645-54. [Medline].

36. [Guideline] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. Aug 4 2004;44(3):E1-E211. [Medline].

37. Lansky AJ, Popma JJ, Massullo V, et al. Quantitative angiographic analysis of stent restenosis in the Scripps Coronary Radiation to Inhibit Intimal Proliferation Post Stenting (SCRIPPS) Trial. Am J Cardiol. Aug 15 1999;84(4):410-4. [Medline].

38. Chaitman BR, Rosen AD, Williams DO, Bourassa MG, Aguirre FV, Pitt B. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation. Oct 7 1997;96(7):2162-70. [Medline].

39. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ. May 19 2009;338:b1807. [Medline].

40. Agency for Healthcare Research and Quality. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. AHRQ: Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=15%20&DocID=57. Accessed May 29, 2009.

41. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. Sep 21 1995;333(12):757-63. [Medline].

42. Burchenal JE, Marks DS, Tift Mann J, et al. Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am J Cardiol. Aug 15 1998;82(4):511-5. [Medline].

43. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. Sep 21 1995;333(12):764-9. [Medline].

44. [Best Evidence] Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. Mar 24 2009;53(12):1021-30. [Medline].

45. [Best Evidence] Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. Jun 2 2009;119(21):2758-64. [Medline].

46. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. Apr 20 1999;99(15):1951-8. [Medline].

47. De Luca G, Suryapranata H, Stone GW. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. Apr 13 2005;293(14):1759-65.

48. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. Aug 21 2003;349(8):733-42. [Medline].

49. Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. Apr 3 2002;39(7):1096-103. [Medline].

50. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. Aug 16 2000;284(7):835-42. [Medline].

51. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. May 1998;31(6):1234-9. [Medline].

52. Antoniucci D, Valenti R, Trapani M, Moschi G. Current role of stenting in acute myocardial infarction. Am Heart J. Aug 1999;138(2 Pt 2):S147-52. [Medline].

53. Atwater BD, Roe MT, Mahaffey KW. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. Drugs. 2005;65(3):313-24. [Medline].

54. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. Aug 3 2004;141(3):186-95. [Medline].

55. Baim DS, Mehran R, Kereiakes DJ, Gross TP, Simons M, Malenka D. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach. Circulation. Feb 14 2006;113(6):891-7. [Medline].

56. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. Jun 2006;35(6):368-78. [Medline].

57. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. Oct 21 1997;96(8):2551-6. [Medline].

58. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris. A report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. Nov 1 1994;24(5):1195-206. [Medline].

59. Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol. Aug 2 2005;46(3):438-42. [Medline].

60. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation. Oct 22 2002;106(17):2284-7. [Medline].

61. Berger PB, Velianou JL, Aslanidou Vlachos H, Feit F, Jacobs AK, Faxon DP. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. Nov 1 2001;38(5):1440-9. [Medline].

62. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. Aug 8 2000;102(6):624-9. [Medline].

63. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. Jan 1 2003;41(1):20-5. [Medline].

64. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. Nov 3 2004;292(17):2096-104. [Medline].

65. Biondi-Zoccai GG, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte M. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J. Mar 2005;149(3):504-11. [Medline].

66. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Airoldi F, Cosgrave J, Chieffo A. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J. Mar 2006;27(5):540-6. [Medline].

67. Bittl JA. Advances in coronary angioplasty. N Engl J Med. Oct 24 1996;335(17):1290-302. [Medline].

68. Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. J Am Coll Cardiol. Mar 17 2004;43(6):936-42. [Medline].

69. Black AJ, Namay DL, Niederman AL, et al. Tear or dissection after coronary angioplasty. Morphologic correlates of an ischemic complication. Circulation. May 1989;79(5):1035-42. [Medline].

70. Blankenship JC, Tasissa G, O'Shea JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol. Sep 2001;38(3):653-8. [Medline].

71. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. Apr 12 2007;356(15):1503-16. [Medline].

72. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. Jan 19 2002;359(9302):189-98. [Medline].

73. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. Sep 14 2002;360(9336):825-9. [Medline].

74. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. Oct 2 2002;40(7):1366-74. [Medline].

75. Brodie BR, Grines CL, Ivanhoe R, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. Circulation. Jul 1994;90(1):156-62. [Medline].

76. Califf RM. Stenting or surgery: an opportunity to do it right. J Am Coll Cardiol. Aug 16 2005;46(4):589-91. [Medline].

77. Cannon CP. Evidence-based risk stratification to target therapies in acute coronary syndromes. Circulation. Sep 24 2002;106(13):1588-91. [Medline].

78. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. Jun 21 2001;344(25):1879-87. [Medline].

79. Casey C, Faxon DP. Multi-vessel coronary disease and percutaneous coronary intervention. Heart. Mar 2004;90(3):341-6. [Medline].

80. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. Feb 20 2001;103(7):961-6. [Medline].

81. Chieffo A, Morici N, Maisano F, Bonizzoni E, Cosgrave J, Montorfano M. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. May 30 2006;113(21):2542-7. [Medline].

82. Cohen MG, Ohman EM. Drug-eluting stents in acute myocardial infarction: is science catching up with practice?. JAMA. May 4 2005;293(17):2154-6. [Medline].

83. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. Aug 19 2003;108(7):788-94. [Medline].

84. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol. Sep 18 2002;40(6):1021-33. [Medline].

85. Cowley MJ, Dorros G, Kelsey SF, Van Raden M, Detre KM. Emergency coronary bypass surgery after coronary angioplasty: the National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry experience. Am J Cardiol. Jun 15 1984;53(12):22C-26C. [Medline].

86. Cura FA, Bhatt DL, Lincoff AM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation. Jul 4 2000;102(1):28-34. [Medline].

87. Dawkins KD, Gershlick T, de Belder M, et al. Percutaneous coronary intervention: recommendations for good practice and training. Heart. Dec 2005;91 Suppl 6:vi1-27. [Medline].

88. de Feyter PJ, Serruys PW, van den Brand M, et al. Emergency coronary angioplasty in refractory unstable angina. N Engl J Med. Aug 8 1985;313(6):342-6. [Medline].

89. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. Apr 21 2004;43(8):1363-7. [Medline].

90. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. Mar 16 2004;109(10):1223-5. [Medline].

91. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. Sep 15 2005;353(11):1095-104. [Medline].

92. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. Sep 15 2005;353(11):1095-104. [Medline].

93. Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. Dec 2 2003;108(22):2747-50. [Medline].

94. Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med. Feb 4 1988;318(5):265-70. [Medline].

95. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. Aug 18 2005;353(7):663-70. [Medline].

96. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J. Jul 2001;142(1):119-26. [Medline].

97. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation. Sep 28 1999;100(13):1464-80. [Medline].

98. Eigler N FJ. Nonpharmacologic Device Prevention of Coronary Restenosis. In: EJ T, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders; 1994:400-414.

99. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation. Dec 1994;90(6):2725-30. [Medline].

100. Ellis SG, Cowley MJ, Whitlow PL. Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 vs 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS). J Am Coll Cardiol. Apr 1995;25(5):1137-42. [Medline].

101. Ellis SG, Omoigui N, Bittl JA, et al. Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. Circulation. Feb 1 1996;93(3):431-9. [Medline].

102. Ellis SG, Roubin GS, King SB 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation. Feb 1988;77(2):372-9. [Medline].

103. Emanuelsson H. Future challenges to coronary angioplasty: perspectives on intracoronary imaging and physiology. J Intern Med. Aug 1995;238(2):111-9. [Medline].

104. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation. Jun 20 2000;101(24):2795-802. [Medline].

105. Ferguson JJ, Barasch E, Wilson JM, et al. The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators. J Invasive Cardiol. Jan-Feb 1995;7(1):2-10. [Medline].

106. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. Jul 7 2004;292(1):45-54. [Medline].

107. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. Feb 5 1994;343(8893):311-22. [Medline].

108. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet. Nov 4 1995;346(8984):1179-84. [Medline].

109. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. Mar 23 2005;293(12):1501-8. [Medline].

110. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol. Jun 1997;29(7):1505-11. [Medline].

111. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. Sep 7 2002;360(9335):743-51. [Medline].

112. FRISC II. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].

113. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. Apr 5 2005;45(7):995-8. [Medline].

114. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. Mar 9 2004;109(9):1085-8. [Medline].

115. Gershlick AH. Drug eluting stents in 2005. Heart. Jun 2005;91 Suppl 3:iii24-31. [Medline].

116. Goy JJ, Stauffer JC, Siegenthaler M, Benoît A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol. Jan 18 2005;45(2):308-11. [Medline].

117. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. Mar 11 1993;328(10):673-9. [Medline].

118. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. Dec 23 1999;341(26):1949-56. [Medline].

119. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. Dec 23 1999;341(26):1949-56. [Medline].

120. Grube E, Buellesfeld L. Paclitaxel-eluting stents: current clinical experience. Am J Cardiovasc Drugs. 2004;4(6):355-60. [Medline].

121. Grzybowski M, Clements EA, Parsons L, Welch R, Tintinalli AT, Ross MA. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. Oct 8 2003;290(14):1891-8. [Medline].

122. GUSTO IIb Angioplasty Substudy. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med. Jun 5 1997;336(23):1621-8. [Medline].

123. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med. Oct 20 1994;331(16):1037-43. [Medline].

124. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. May 26 2005;352(21):2174-83. [Medline].

125. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. Jan 24 2008;358(4):331-41. [Medline].

126. Hillegass WB OE, Califf RM. Restenosis: The Clinical Issues. In: EJ T, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders; 1994:415-435.

127. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. Aug 26 1999;341(9):625-34. [Medline].

128. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. Jan 10 2001;285(2):190-2. [Medline].

129. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol. Apr 16 2003;41(8):1293-304. [Medline].

130. Holmes D, Fitzgerald P, Goldberg S, et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J. Jan 2000;139(1 Pt 1):23-31. [Medline].

131. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. Feb 10 2004;109(5):634-40. [Medline].

132. Holmes DR Jr, Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation. Apr 1 1995;91(7):1966-74. [Medline].

133. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. Dec 1995;26(7):1600-5. [Medline].

134. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. May 4 2005;293(17):2126-30. [Medline].

135. IMPACT-II study. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. May 17 1997;349(9063):1422-8. [Medline].

136. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. Apr 27 2004;109(16):1930-2. [Medline].

137. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. Dec 7 2004;44(11):2133-6. [Medline].

138. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. Mar 2004;147(3):457-62. [Medline].

139. [Best Evidence] Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. Dec 19 2006;48(12):2440-7. [Medline].

140. Kandzari DE, Roe MT, Ohman EM, Milford-Beland S, Chen AY, Lytle BL. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. Sep 15 2005;96(6):750-5. [Medline].

141. Kandzari DE, Roe MT, Ohman EM, Milford-Beland S, Chen AY, Lytle BL. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. Sep 15 2005;96(6):750-5. [Medline].

142. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. Jan 1 2003;41(1):26-32. [Medline].

143. Kastrati A, Dibra A, Eberle S, Mehilli J, Suárez de Lezo J, Goy JJ. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. Aug 17 2005;294(7):819-25. [Medline].

144. Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet. Mar 16 2002;359(9310):920-5. [Medline].

145. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. Jan 15 2004;350(3):232-8. [Medline].

146. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. Jan 12 2005;293(2):165-71. [Medline].

147. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. Feb 18 2006;367(9510):579-88. [Medline].

148. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. Jan 4 2003;361(9351):13-20. [Medline].

149. Kelly RV, Cohen MG, Ohman EM. Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove!. Am Heart Hosp J. 2004;2(4):211-22. [Medline].

150. Kelly RV, Cohen MG, Runge MS, Stouffer GA. The no-reflow phenomenon in coronary arteries. J Thromb Haemost. Nov 2004;2(11):1903-7. [Medline].

151. Kelly RV, Steinhubl S. Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart. Jun 2005;91 Suppl 3:iii16-9. [Medline].

152. Kent KM, Bentivoglio LG, Block PC, et al. Long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA): report from the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol. Jun 15 1984;53(12):27C-31C. [Medline].

153. King SB 3rd. Angioplasty from bench to bedside to bench. Circulation. May 1 1996;93(9):1621-9. [Medline].

154. King SB 3rd, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med. Oct 20 1994;331(16):1044-50. [Medline].

155. Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease?. J Am Coll Cardiol. Jan 3 2006;47(1):22-6. [Medline].

156. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. Dec 22-29 1998;98(25):2829-35. [Medline].

157. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. Jan 1993;21(1):15-25. [Medline].

158. Kurbaan AS, Bowker TJ, Ilsley CD, Rickards AF. Impact of postangioplasty restenosis on comparisons of outcome between angioplasty and bypass grafting. Coronary Angioplasty versus Bypass Revascularisation Investigation (CABRI) Investigators. Am J Cardiol. Aug 1 1998;82(3):272-6. [Medline].

159. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv. Jan 2000;49(1):19-22. [Medline].

160. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation. Mar 9 2004;109(9):1114-20. [Medline].

161. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. Dec 3 1998;339(23):1665-71. [Medline].

162. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. Feb 19 2003;289(7):853-63. [Medline].

163. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. Jul 29 1999;341(5):319-27. [Medline].

164. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. Aug 11 2004;292(6):696-703. [Medline].

165. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. Jan 2 1986;314(1):1-6. [Medline].

166. MacDonald RG, Feldman RL, Conti CR, Pepine CJ. Thromboembolic complications of coronary angioplasty. Am J Cardiol. Oct 1 1984;54(7):916-7. [Medline].

167. MacNeill BD, Jang IK, Bouma BE, Iftimia N, Takano M, Yabushita H. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol. Sep 1 2004;44(5):972-9. [Medline].

168. Mahaffey KW, Ferguson JJ. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. Am Heart J. Apr 2005;149(4 Suppl):S81-90. [Medline].

169. Matar FA, Mintz GS, Farb A, et al. The contribution of tissue removal to lumen improvement after directional coronary atherectomy. Am J Cardiol. Oct 1 1994;74(7):647-50. [Medline].

170. McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol. Sep 1998;32(3):596-605. [Medline].

171. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. Feb 2006;27(3):260-6. [Medline].

172. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. Jun 15 2005;293(23):2908-17. [Medline].

173. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. Aug 18 2001;358(9281):527-33. [Medline].

174. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. Jul 1 1996;94(1):35-43. [Medline].

175. Mishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol. Dec 1999;34(7):1884-90. [Medline].

176. Monassier JP, Hamon M, Elias J, et al. Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction). Cathet Cardiovasc Diagn. Nov 1997;42(3):243-8. [Medline].

177. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. Jun 21 2001;344(25):1895-903. [Medline].

178. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. Jul 21 2004;292(3):362-6. [Medline].

179. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. Jun 6 2002;346(23):1773-80. [Medline].

180. Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. Jul 2001;38(1):143-9. [Medline].

181. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. Oct 2 2003;349(14):1315-23. [Medline].

182. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. Jan 1995;129(1):146-72. [Medline].

183. Murphy ML, Hultgren HN, Detre K, Thomsen J, Takaro T. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med. Sep 22 1977;297(12):621-7. [Medline].

184. Myler R. Coronary and Peripheral Angioplasty: Historic Perspective. 2^nd ed. Philadelphia, Pa: WB Saunders, Co; 1993.

185. Myler RK, Shaw RE, Stertzer SH. Unstable angina and coronary angioplasty. Circulation. Sep 1990;82(3 Suppl):II88-95. [Medline].

186. Nakagawa Y, Iwasaki Y, Kimura T. Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. Am J Cardiol. Nov 1 1996;78(9):980-4. [Medline].

187. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol. Oct 1 2003;92(7):824-6. [Medline].

188. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol. Apr 2001;37(5):1323-8. [Medline].

189. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. Sep 24 2003;290(12):1593-9. [Medline].

190. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. Mar 15 2000;35(4):915-21. [Medline].

191. Niccoli G, Testa L, Mongiardo R, et al. Directional atherectomy before stenting versus stenting alone in percutaneous coronary interventions: a meta-analysis. Int J Cardiol. Sep 20 2006;112(2):178-83. [Medline].

192. Nissen SE, De Franco AC, Tuzcu EM, Moliterno DJ. Coronary intravascular ultrasound: diagnostic and interventional applications. Coron Artery Dis. May 1995;6(5):355-67. [Medline].

193. O'Neill WW. Mechanical rotational atherectomy. Am J Cardiol. May 7 1992;69(15):12F-18F. [Medline].

194. O'Neill WW, Brodie BR, Ivanhoe R, et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). Am J Cardiol. Apr 1 1994;73(9):627-34. [Medline].

195. O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. Feb 6 2002;287(5):618-21. [Medline].

196. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. Mar 15 2005;45(6):947-53. [Medline].

197. Ong AT, Serruys PW. Drug-eluting stents: current issues. Tex Heart Inst J. 2005;32(3):372-7. [Medline].

198. Orlic D, Bonizzoni E, Stankovic G, Airoldi F, Chieffo A, Corvaja N. Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol. Apr 7 2004;43(7):1154-60. [Medline].

199. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. Apr 17 2003;348(16):1537-45. [Medline].

200. Patel TN, Bavry AA, Kumbhani DJ, Ellis SG. A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis. Am J Cardiol. Jun 15 2006;97(12):1685-90. [Medline].

201. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. Apr 26 2005;111(16):2099-106. [Medline].

202. Penny WF, Schmidt DA, Safian RD, Erny RE, Baim DS. Insights into the mechanism of luminal improvement after directional coronary atherectomy. Am J Cardiol. Feb 15 1991;67(5):435-7. [Medline].

203. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. Jul 7 2004;292(1):89-96. [Medline].

204. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. Jun 1994;89(6):2514-8. [Medline].

205. Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. Dec 1 1995;92(11):3183-93. [Medline].

206. Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. Apr 1993;87(4):1354-67. [Medline].

207. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. Sep 2004;126(3 Suppl):576S-599S. [Medline].

208. Rodriguez A, Bernardi V, Fernandez M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol. Jun 1 1998;81(11):1286-91. [Medline].

209. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol. Jan 2001;37(1):51-8. [Medline].

210. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart. May 2006;92(5):641-9. [Medline].

211. Ryan JW, Peterson ED, Chen AY, et al. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. Nov 15 2005;112(20):3049-57. [Medline].

212. Saber RS, Edwards WD, Bailey KR, McGovern TW, Schwartz RS, Holmes DR Jr. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. J Am Coll Cardiol. Nov 1 1993;22(5):1283-8. [Medline].

213. Safian RD, Gelbfish JS, Erny RE, Schnitt SJ, Schmidt DA, Baim DS. Coronary atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms. Circulation. Jul 1990;82(1):69-79. [Medline].

214. Saito S, Hosokawa G, Tanaka S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv. Nov 1999;48(3):262-8. [Medline].

215. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. Aug 10 2000;343(6):385-91. [Medline].

216. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. Jan 1997;29(1):28-34. [Medline].

217. Schomig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schuhlen H. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. Jul 2005;26(14):1379-84. [Medline].

218. Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. Jun 30 1988;318(26):1714-9. [Medline].

219. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. Feb 2 2006;354(5):483-95. [Medline].

220. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. Aug 16 2005;46(4):575-81. [Medline].

221. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. Apr 12 2001;344(15):1117-24. [Medline].

222. [Guideline] Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. Apr 2005;26(8):804-47. [Medline].

223. [Guideline] Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. Jan 3 2006;47(1):e1-121. [Medline].

224. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. Sep 28 2002;360(9338):965-70. [Medline].

225. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation. May 6 2003;107(17):2274-9. [Medline].

226. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation. May 13 2003;107(18):2383-9. [Medline].

227. Srinivas VS, Brooks MM, Detre KM, King SB 3rd, Jacobs AK, Johnston J. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation. Sep 24 2002;106(13):1627-33. [Medline].

228. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. Nov 20 2002;288(19):2411-20. [Medline].

229. Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. Mar 30 1999;99(12):1548-54. [Medline].

230. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. Sep 14 2005;294(10):1215-23. [Medline].

231. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. Jan 15 2004;350(3):221-31. [Medline].

232. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. Apr 27 2004;109(16):1942-7. [Medline].

233. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. Mar 28 2002;346(13):957-66. [Medline].

234. [Best Evidence] Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. Apr 23 2008;299(16):1903-13. [Medline].

235. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. Mar 8 2007;356(10):998-1008. [Medline].

236. Storger H, Grube E, Hofmann M, Schwarz F, Haase J. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. J Interv Cardiol. Dec 2004;17(6):387-90. [Medline].

237. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation. Jun 20 2000;101(24):2788-94. [Medline].

238. Suryapranata H, van 't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. Jun 30 1998;97(25):2502-5. [Medline].

239. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. Aug 7 1997;337(6):365-72. [Medline].

240. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. Jun 12 1997;336(24):1697-703. [Medline].

241. The Bypass Angioplasty Revascularization Investigation (BARI). Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. Sep 16 1997;96(6):1761-9. [Medline].

242. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. Jul 25 1996;335(4):217-25. [Medline].

243. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. Apr 7 1994;330(14):956-61. [Medline].

244. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. Jun 12 1997;336(24):1689-96. [Medline].

245. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. Jul 11 1998;352(9122):87-92. [Medline].

246. The Randomized Intervention Treatment of Angina (RITA) trial. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet. Mar 6 1993;341(8845):573-80. [Medline].

247. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. Sep 2 1997;96(5):1445-53. [Medline].

248. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Circulation. Jul 1992;86(1):121-30. [Medline].

249. Tolleson TR, O'Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. Feb 5 2003;41(3):386-93. [Medline].

250. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. Jan 15 2009;360(3):213-24. [Medline].

251. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med. Jul 22 1993;329(4):221-7. [Medline].

252. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. Jul 2002;113(1):1-6. [Medline].

253. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. Dec 11 1999;354(9195):2019-24. [Medline].

254. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. Jun 21 2001;344(25):1888-94. [Medline].

255. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. Jul 6 1999;100(1):21-6. [Medline].

256. van Domburg RT, Foley DP, Breeman A, van Herwerden LA, Serruys PW. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J. Apr 2002;23(7):543-9. [Medline].

257. [Best Evidence] Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. Jun 7 2008;371(9628):1915-20. [Medline].

258. Waksman R, Bhargava B, White L, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation. Apr 25 2000;101(16):1895-8. [Medline].

259. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. May 9 2000;101(18):2165-71. [Medline].

260. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. Jul 1 2000;356(9223):9-16. [Medline].

261. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. Dec 17 1997;278(23):2093-8. [Medline].

262. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol. Apr 15 1995;75(12):849-50. [Medline].

263. Whitlow PL, Dimas AP, Bashore TM, Califf RM, Bourassa MG, Chaitman BR. Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. Nov 15 1999;34(6):1750-9. [Medline].

264. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. Dec 12 2000;102(24):2945-51. [Medline].

265. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. Aug 18 2005;353(7):653-62. [Medline].

266. Wolfe MW, Roubin GS, Schweiger M, et al. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Heparin Registry Investigators. Circulation. Aug 1 1995;92(3):311-9. [Medline].

267. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol. Dec 6 2005;46(11):2004-9. [Medline].

268. Yock PG, Fitzgerald PJ. Intravascular ultrasound: state of the art and future directions. Am J Cardiol. Apr 9 1998;81(7A):27E-32E. [Medline].

269. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. Aug 27 1994;344(8922):563-70. [Medline].

270. Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. Circulation. Jun 1 1996;93(11):1954-62. [Medline].

Further Reading

Keywords

percutaneous transluminal coronary angioplasty, STEMI, guidelines, coronary artery disease, coronary artery bypass surgery, CABG, unstable angina, myocardial infarction, percutaneous coronary interventions balloon angioplasty, intracoronary stents

Contributor Information and Disclosures

Author

George A Stouffer III, MD, Henry A Foscue Distinguished Professor of Medicine and Cardiology, Director of Interventional Cardiology, Cardiac Catheterization Laboratory, Chief of Clinical Cardiology, Division of Cardiology, University of North Carolina Medical Center
George A Stouffer III, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American Heart Association, Phi Beta Kappa, and Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Coauthor(s)

Josh W Todd, MD, Fellow in General Cardiology, University of North Carolina at Chapel Hill
Josh W Todd, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, and American Heart Association
Disclosure: Nothing to disclose.

Jorge Davalos, MD, Interventional Cardiology Fellow, University of North Carolina at Chapel Hill
Jorge Davalos, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Medical Association, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Gregory J Dehmer, MD, Director, Division of Cardiology, Scott & White Healthcare; Professor of Medicine, Texas A&M Health Science Center College of Medicine
Gregory J Dehmer, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, Society for Cardiac Angiography and Interventions, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Marschall S Runge, MD, PhD, Charles and Anne Sanders Distinguished Professor of Medicine, Chairman, Department of Medicine, Vice Dean for Clinical Affairs, University of North Carolina at Chapel Hill School of Medicine
Marschall S Runge, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society for Investigative Pathology, Association of American Physicians, Association of Professors of Cardiology, Association of Professors of Medicine, Southern Society for Clinical Investigation, and Texas Medical Association
Disclosure: Pfizer Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Orthoclinica Diagnostica Consulting fee Consulting

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Karlheinz Peter, MD, PhD, Professor of Medicine, Monash University; Head of Centre of Thrombosis and Myocardial Infarction, Head of Division of Atherothrombosis and Vascular Biology, Associate Director, Baker Heart Research Institute; Interventional Cardiologist, The Alfred Hospital, Australia
Karlheinz Peter, MD, PhD is a member of the following medical societies: American Heart Association, Cardiac Society of Australia and New Zealand, and German Cardiac Society
Disclosure: Nothing to disclose.